CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for EirGenix Inc is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

EirGenix Inc
Phone: +886 277080123p:+886 277080123 NEW TAIPEI, 221  Taiwan Ticker: 65896589
Business Summary
EirGenix Inc is a Taiwan-based company primarily engaged in the development of antibody drugs and the manufacture of biopharmaceuticals. Its main businesses include the provision of Contract Development & Manufacturing Organization (CDMO) services, the construction of cell strain, the manufacture of clinical trial medicine, analytical science and protein identification, and PIC/S manufacturing plant to provide clinical trial drug production.
(Source: N-30D)

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
YesYes-----

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
6/30/202412/31/2023Yes----

Industries
SIC Code Description
2836 Biological products, except diagnostic substances
8731 Commercial physical and biological research

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Chairman of the Board, General Manager, Chief Executive Officer-BioPharma Business Unit Lee-ChengLiu 1/1/2023
Chief Financial Officer, Deputy General Manager, Corporate Governance Officer Hsiu-ChuanYang 5/3/2016 5/3/2016
Chief Executive Officer-BioManufacturing Business Unit, Senior Deputy General Manager Chih-JungChang 1/1/2023
6 additional Officers and Directors records available in full report.

General Information
Number of Employees: 207 (As of 12/31/2019)
Outstanding Shares: 305,711,233 (As of 10/8/2024)
Shareholders: 31,042
Stock Exchange: TPO
Fax Number: +886 277081666


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Wednesday, November 20, 2024